BNTX:NASDAQ
BioNTech SE
US$ 96.90
arrow_upward
+0.05%(+0.050) Siku 1
US$ 96.14
arrow_downward
-0.78% (-0.76)todayKabla ya soko
Imefungwa: 2 Okt, 16:00:01 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya BNTX...
Fungua
US$ 97.35
Juu
US$ 98.00
Chini
US$ 96.22
Mtaji wa soko
24.34B
Wastani wa kiasi cha mauzo
1.19M
Kiasi cha mauzo ya hisa
elfu 1.28
Juu kwa wiki 52
US$ 123.98
Chini kwa wiki 52
US$ 79.52
EPS
-US$ 7.55
Beta
1.22
Hisa za wawekezaji
251.20M
Idadi ya wafanyakazi
elfu 8
Fungua
US$ 97.35
Juu
US$ 98.00
Chini
US$ 96.22
Mtaji wa soko
24.34B
Wastani wa kiasi cha mauzo
1.19M
Kiasi cha mauzo ya hisa
elfu 1.28
Juu kwa wiki 52
US$ 123.98
Chini kwa wiki 52
US$ 79.52
EPS
-US$ 7.55
Beta
1.22
Hisa za wawekezaji
251.20M
Idadi ya wafanyakazi
elfu 8
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
AD HOC NEWS
·
saa 2 zilizopita
Berenberg raises target for BioNTech stock from USD 132 to USD 140
AD HOC NEWS
·
saa 17 zilizopita
BioNTech stock faces a 59.5 percent Q2 revenue drop
Seeking Alpha
·
saa 19 zilizopita
BioNTech SE: Moving Past Covid (NASDAQ:BNTX)
AD HOC NEWS
·
siku 1 iliyopita
CureVac stock converts into BioNTech shares after merger
Wasifu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Kuhusu BioNTech SE